- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT00962312
Lapatinib Ditosylate and Capecitabine in Treating Patients With Metastatic Pancreatic Cancer
A Phase II Study of Lapatinib and Capecitabine in the Treatment of Metastatic Pancreatic Cancer.
RATIONALE: Lapatinib ditosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving lapatinib ditosylate together with capecitabine may kill more tumor cells.
PURPOSE: This phase II trial is studying how well giving lapatinib ditosylate together with capecitabine works in treating patients with metastatic pancreatic cancer.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
OBJECTIVES:
Primary
- To evaluate the efficacy of lapatinib ditosylate and capecitabine as first-line therapy, in terms of overall survival, in patients with metastatic pancreatic cancer.
Secondary
- To evaluate the progression-free survival of patients treated with this regimen.
- To evaluate the overall response rate (complete and partial responses) in patients treated with this regimen.
- To evaluate the clinical benefit (complete response, partial response, or stable disease for ≥ 6 months) of this regimen in these patients.
- To evaluate the qualitative and quantitative toxicity associated with this regimen in these patients.
- To determine the intra-tumoral expression of ErbB1 (EGFR) and ErbB2 (HER2/neu) in these patients.
- To seek pilot information on the intra-tumoral expression of markers of tumor resistance and sensitivity to treatment, including resistance drug pump expression and growth factor receptor expression.
- To collect pre- and post-treatment serum samples from these patients for proteomic analyses to elucidate if any serum cancer marker profiles can be detected.
OUTLINE: This is a multicenter study.
Patients receive oral lapatinib ditosylate once daily on days 1-21 and oral capecitabine twice daily on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up every 6-12 weeks.
Tipo de estudio
Inscripción (Actual)
Fase
- Fase 2
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
-
Cork, Irlanda
- Cork University Hospital
-
Cork, Irlanda
- Mercy University Hospital
-
Dublin, Irlanda, 9
- Beaumont Hospital
-
Dublin, Irlanda, 7
- Mater Misericordiae University Hospital
-
Dublin, Irlanda, 4
- St. Vincent's University Hospital
-
Dublin, Irlanda, 7
- Mater Private Hospital
-
Dublin, Irlanda, 24
- Adelaide and Meath Hospital, Dublin Incorporating the National Children's Hospital
-
Dublin, Irlanda, 8
- St. James's Hospital
-
Galway, Irlanda
- University College Hospital
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
DISEASE CHARACTERISTICS:
- Histologically or cytologically confirmed metastatic adenocarcinoma of the pancreas
Measurable or non-measurable disease
- Measurable disease is defined as ≥ 1 lesion that can be accurately measured in ≥ 1 dimension (longest diameter to be recorded) as ≥ 20 mm with conventional techniques or as ≥ 10 mm with spiral CT scan
- No known brain metastases or leptomeningeal disease
PATIENT CHARACTERISTICS:
- ECOG performance status 0-1
- Life expectancy > 12 weeks
- ANC ≥ 1,500/mm^3
- Platelet count ≥ 100,000/mm^3
- Hemoglobin ≥ 9 g/dL
- Albumin ≥ 2.5 g/dL
- Serum bilirubin ≤ 1.5 times upper limit of normal (ULN) (2.5 times ULN if Gilbert's syndrome is present)
- AST and ALT ≤ 3 times ULN (5 times ULN if documented liver metastases are present)
- Creatinine < 1.5 times ULN
- Cardiac ejection fraction normal by ECHO or MUGA scan
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception
- Able to swallow and retain oral medication
- No gastrointestinal (GI) tract disease resulting in an inability to take oral medication, malabsorption syndrome, requirement for IV alimentation, or uncontrolled inflammatory GI disease (e.g., Crohn's disease or ulcerative colitis)
- No active hepatic or biliary disease, except for Gilbert's syndrome, asymptomatic gallstones, liver metastases, or stable chronic liver disease per investigator assessment
No active cardiac disease within the past 6 months, including any of the following:
- Uncontrolled angina
- Clinically significant arrhythmia, except for asymptomatic atrial fibrillation requiring anticoagulation
- Myocardial infarction
- Uncontrolled or symptomatic congestive heart failure
- Any other cardiac condition that, in the opinion of the treating physician, would make this study unreasonably hazardous for the patient
- No concurrent uncontrolled illness including, but not limited to, ongoing or active infection or psychiatric illness/social situation that would limit compliance with study requirements
- No known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to lapatinib ditosylate or any of its excipients, capecitabine, or fluorouracil
- No known dihydropyrimidine dehydrogenase (DPD) deficiency
- No other malignancy within the past 5 years except for completely resected nonmelanoma skin cancer or successfully treated in situ carcinoma
PRIOR CONCURRENT THERAPY:
- Recovered from prior radiotherapy or surgery
- No prior surgical procedures affecting absorption
- No prior EGFR- or ErbB2-targeting therapies
- No prior capecitabine
- No prior chemotherapy for locally advanced or metastatic pancreatic cancer
At least 3 months since prior adjuvant chemotherapy
- Prior fluorouracil allowed as a radiosensitizer only
- More than 30 days (or 5 half-lives) since prior investigational drugs
- No concurrent radiotherapy or surgery for metastatic cancer
- No concurrent combination antiretroviral therapy for HIV-positive patients
- No concurrent CYP3A4 inducers or inhibitors
- No other concurrent investigational agents or anticancer therapy (e.g., cytotoxic or biologic therapy)
- No concurrent herbal (alternative) medicines
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: N / A
- Modelo Intervencionista: Asignación de un solo grupo
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
---|---|
Experimental: Capecitabine and Lapatinib
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Periodo de tiempo |
---|---|
6-month survival rate
Periodo de tiempo: 6 months
|
6 months
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Progression-free survival
Periodo de tiempo: 6 months
|
Progression-free survival (PFS) will be measured as the number of days between patient's enrolment and his or her date of progression of disease.
Patients who are still living six months after the last patient has been enrolled will be censored for the analyses, using the number of days between enrolment and the date of last follow-up.
Disease progression will be determined according to definitions established in the modified response evaluation criteria in solid tumours (RECIST) (refer to Appendix G).
For patients with non-measureable tumours disease progression will be determined by the treating physician in consultation with the Chief investigator for the study.
|
6 months
|
Overall response rate
Periodo de tiempo: up to 6 months
|
The overall response rate will be an aggregation of the complete responses and partial responses.
For patients to be given the status of complete response or partial response a confirmatory disease assessment should be performed no less than four weeks after the criteria for response are first met.
|
up to 6 months
|
Clinical benefit
Periodo de tiempo: 6 months
|
A patient will be regarded as' having experienced clinical benefit if they have shown a complete response, a partial response, or stable disease for at least six months.
|
6 months
|
Safety and tolerability
Periodo de tiempo: Throughout course of study
|
Throughout course of study
|
|
Tumour biomarker analysis
Periodo de tiempo: Currently ongoing
|
Characterising the patient population by determination of intra-tumoural expression of ErbB1 (EGFR) and ErbB2 (Her2/neu).Seeking pilot information as to the intra-tumoural expression of markers of tumour resistance and sensitivity to treatment.
Proteomic analysis of serum samples for potential markers.
|
Currently ongoing
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Ray McDermott, MD, Adelaide and Meath Hospital, Dublin Incorporating the National Children's Hospital
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio
Finalización primaria (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Estimar)
Actualizaciones de registros de estudio
Última actualización publicada (Estimar)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Enfermedades del Sistema Digestivo
- Neoplasias
- Neoplasias por sitio
- Enfermedades del sistema endocrino
- Neoplasias del Sistema Digestivo
- Neoplasias de glándulas endocrinas
- Enfermedades pancreáticas
- Neoplasias pancreáticas
- Mecanismos moleculares de acción farmacológica
- Inhibidores de enzimas
- Antimetabolitos, Antineoplásicos
- Antimetabolitos
- Agentes antineoplásicos
- Inhibidores de la proteína quinasa
- Capecitabina
- Lapatinib
Otros números de identificación del estudio
- 08-39 ICORG
- ICORG-08-39
- EUDRACT-2008-006907-22
- EU-20933
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .
Ensayos clínicos sobre Cancer de pancreas
-
Abramson Cancer Center of the University of PennsylvaniaTerminadoPaciente con cancerEstados Unidos
-
Peking Union Medical College HospitalTerminadoEncuesta | Estado nutricional | Paciente con cancerPorcelana
-
Ankara Medipol UniversityReclutamientoCuidados personales | Inmunoterapia | Manejo de síntomas | Paciente con cancerPavo
-
Northwestern UniversityGenzyme, a Sanofi CompanyRetiradoCANCER DE PROSTATAEstados Unidos
-
Fundacao ChampalimaudTerminado
-
University College London HospitalsTerminado
-
GenSpera, Inc.RetiradoCancer de prostata.Estados Unidos
-
University of Colorado, DenverColorado State UniversityRetiradoRealidad virtual | Diagnóstico por imagen | Educación del paciente | Paciente con cancerEstados Unidos
-
Dana-Farber Cancer InstituteTerminadoCancer de RIÑON | Cancer de prostata | Cáncer genitourinarioEstados Unidos
-
Rabin Medical CenterReclutamiento